Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
NCT07920159Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jan 2027
- Primary completion
- Sep 2028
01
Overview
Phase 2, open-label, single-arm trial of suvemcitug in High-Grade Serous Ovarian Carcinoma (HGSOC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-Free Survival at 36 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
suvemcitug
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT07920159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920159.